Nation oder Konfession?

Von Alexander Stern

Tolstoi, Zola und das Judentum

von Simon Stern

Die Familie Lourié (Luria)

von Anton Lourié

Ueber Gesetz und Geschichte der Leichenbestattung und über diesbezügliche Bräuche und Mißbräuche : mit Bezug auf d. Schweizer Leichenverbrennungsfrage

von A. Stern

Grundriss zur Geschichte der Juden und ihrer Literatur

in tabellar. Form bearb. von M. Stern

Die Zerstörung der Stadt Worms im Jahre 1689

... dargest. von F. Soldan

ʻEn ha-ḳore : gründliche Lehre und Anwendung der hebräischen Accentuation ; mit 900 nachweisenden Stellen

von Hermann Stern

Maslul leshon ʿever (Masslul leschon eber) : ein vollständig zum Vortrage geeignetes in Fragen und Antworten eingerichtetes Handbuch der ebräischen Sprache ; als Wiederholungsbuch für die Jugend. Nebst einem Anhange enthaltend Uebersetzungs-Aufgaben vom Deutschen in's Ebräische

von M. E. Stern

Recenzya dzieła pod tytułem : "Slownik Hebrayski i pokrew: dyalektami arab: chald: i syryackim, po krótce obiasniony; przez A. L. Chiarini ... z textu Lacińskiego przełozył P. Chlebowski ... : przez miłosnika łiteratury

Verf. erm. im WorldCat. - Teilw. in hebr. Schr.

Salomon Kajjem Kaddisch, der erste kurbrandenburgische Landrabbiner : nach d. Akten d. geheimen Staatsarchivs z. Berlin

von Moritz Stern

Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study.

BACKGROUND & AIMS The safety and efficacy of the interferon-free combination of faldaprevir (NS3/A4 protease inhibitor), deleobuvir (BI 207127, non-nucleoside polymerase inhibitor), and ribavirin in treatment-naïve patients chronically infected with HCV genotype-1 was explored. METHODS SOUND-C3 was a multicenter, open-label Phase 2b study. Treatment-naïve patients chronically infected with HCV genotype-1a (IL28B CC genotype only; n = 12) and genotype-1b (n = 20) were assigned to 16 weeks of treatment with faldaprevir 120 mg once daily, deleobuvir 600 mg twice daily, and weight-based ribavirin. Patients with compensated liver disease, including cirrhosis, were eligible for inclusion in this study. The primary endpoint was sustained virological response 12 weeks after completion of therapy. RESULTS Sustained virological response rates 12 weeks after completion of therapy were 17% and 95% in patients infected with HCV genotype-1a and genotype-1b respectively. All four patients with cirrhosis achieved sustained virological response 12 weeks after completion of therapy. The most frequently reported adverse events of at least moderate intensity were anaemia (16%), nausea, vomiting and fatigue (9% each). Three (9%) patients discontinued because of adverse events. CONCLUSIONS The interferon-free regimen of faldaprevir, deleobuvir and ribavirin was efficacious in patients infected with genotype-1b and generally well tolerated.

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.

BACKGROUND & AIMS The efficacy and tolerability of faldaprevir, a potent hepatitis C virus (HCV) NS3/4A protease inhibitor, plus peginterferon and ribavirin was assessed in a double-blind, placebo-controlled phase 3 study of treatment-naïve patients with HCV genotype-1 infection. METHODS Patients were randomly assigned (1:2:2) to peginterferon/ribavirin plus: placebo (arm 1, n=132) for 24 weeks; faldaprevir (120 mg, once daily) for 12 or 24 weeks (arm 2, n=259); or faldaprevir (240 mg, once daily) for 12 weeks (arm 3, n=261). In arms 2 and 3, patients with early treatment success (HCV RNA <25 IU/mL at week 4 and undetectable at week 8) stopped all treatment at week 24. Other patients received peginterferon/ribavirin until week 48 unless they met futility criteria. The primary endpoint was sustained virologic response 12 weeks post-treatment (SVR12). RESULTS SVR12 was achieved by 52%, 79%, and 80% of patients in arms 1, 2, and 3, respectively (estimated difference for arms 2 and 3 versus arm 1: 27%, 95% confidence interval 17%-36%; and 29%, 95% confidence interval, 19%-38%, respectively; P<.0001 for both). Early treatment success was achieved by 87% (arm 2) and 89% (arm 3) of patients, of whom 86% and 89% achieved SVR12. Adverse event rates were similar among groups; few adverse events led to discontinuation of all regimen components. CONCLUSIONS Faldaprevir plus peginterferon/ribavirin significantly increased SVR12, compared with peginterferon/ribavirin, in treatment-naïve patients with HCV genotype-1 infection. There do not seem to be any differences in responses of patients given once-daily 120 or 240 mg faldaprevir.

Ozar ha-millin : ein vollständiges kurzgefasstes talmudisch-aramäisch-chaldäisches Handwörterbuch zum Verständniß des Talmuds und der Midraschim

nach den besten ältesten und neuesten Hülfsquellen bearb. von M. E. Stern

"Ozar Sefath Kodesch" : vollständiges, kurzgefaßtes Wörterbuch der ebräischen Sprache mit Angabe aller in der heiligen Schrift gebräuchlichen Conjugationen ; zum Gebrauche für Schulen und Laien ; ebräisch-deutscher Theil

von M. E. Stern